Use of the cardiovascular polypill 40 mg in secondary cardiovascular prevention
Por:
Marzal D, Rodríguez Padial L, Arnáiz JA, Castro A, Cosín J, Lekuona I and Guijarro C
Publicada:
1 sep 2018
Resumen:
Controlling cardiovascular risk factors (CV) is essential for patients with cardiovascular disease. The CV polypill contains aspirin 100 mg, atorvastatin 20 mg or 40 mg, and ramipril 2.5 mg, 5 mg or 10 mg in a fixed combination pill. The objective was to review the evidence on the secondary prevention of cardiovascular disease, to establish the eventual patient profiles suitabtes to consider the use of CV polypill with atorvastatin 40 mg in secondary CV prevention (P40PS), and to define the priority situations most adequate for the use of P40PS. A bibliographic review was carried out, which was complemented with the clinical opinion of 19 specialists. During hospitalization and discharge, P40PS is an option for patients admitted because of an atherothrombotic event, peripheral arterial disease, or other causes, and with the indication of the monocomponents. Its priority use is proposed in: prior intolerance to the highest dose of atorvastatin (80 mg), age >75 years, low weight, stage 3 of chronic renal failure, hypothyroidism, drug interactions and Asian origin. Outside the hospital setting, the P40PS is a therapeutic alternative in patients with a need for secondary CV prevention and with indication to receive the monocomponents. The priority situations to receive the P40PS are: to be taking the three components separately, to require polypharmacy, lack of adherence or understanding of the treatment, and lack of control of CV risk factors. This work is the first with proposals for the use of P40PS and can facilitate the treatment of patients with cardiovascular disease in secondary prevention. (C) 2018 Sociedad Espanola de Arteriosclerosis. Published by Elsevier Espana, S.L.U. All rights reserved.
Filiaciones:
Marzal D:
Hospital Virgen del Mar, Madrid, España
Rodríguez Padial L:
Complejo Hospitalario Universitario de Toledo, Toledo, España
Arnáiz JA:
Hospital Clínic, Barcelona, España
Castro A:
Hospital Universitario La Paz, Madrid, España
:
Hospital Arnau de Vilanova, Valencia, España
Lekuona I:
Hospital Galdakao, Galdakao, Bizkaia, España
Guijarro C:
Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, Alcorcón, Madrid, España
|